A gene expression prognostic signature for overall survival in patients with high-grade serous ovarian cancer.

A gene expression prognostic signature for overall survival in patients with high-grade serous ovarian cancer.

Accepted version

Peer-reviewed

Repository URI

https://www.repository.cam.ac.uk/handle/1810/315175

Repository DOI

https://doi.org/10.17863/CAM.62283

Files

Accepted version (1.9 MB)

Type

Conference Object

Authors

Millstein, Joshua

Budden, Timothy

Anglesio, Michael

Beeghly-Fadiel, Alicia

Keywords

32 Biomedical and Clinical Sciences, 3211 Oncology and Carcinogenesis, Rare Diseases, Women's Health, Orphan Drug, Genetics, Clinical Research, Cancer, Cancer Genomics, Human Genome, Ovarian Cancer, Precision Medicine, 4.4 Population screening, Cancer, 3 Good Health and Well Being

Journal Title

Journal of Clinical Oncology

Journal ISSN

0732-183X
1527-7755

Volume Title

36

Publisher

American Society of Clinical Oncology (ASCO)

Publisher DOI

https://doi.org/10.1200/jco.2018.36.15_suppl.5583

Rights and licensing

All rights reserved

Except where otherwised noted, this item's license is described as All rights reserved

Sponsorship

Cancer Research Uk (None)
National Institutes of Health (NIH) (via H Lee Moffitt Cancer Center & Research Institute) (SUBAWARD # 10-15915-01-03-G2)
Congressionally Directed Medical Research Programs (CDMRP) (via (BD521555)
National Institutes of Health (NIH) (via Cedars-Sinai Medical Center) (sub award 0001331845)
H. Lee Moffitt Cancer Center & Research Institute (8604)

Collections

University of Cambridge Research Outputs (Articles and Conferences)